Screening and early detection of prostate cancer: PSA and beyond
Poster Session 18
-
Location:Room Stockholm, North Hall (Level 1)
-
Chairs:
-
Aims and objectives of this session The session is aimed at addressing the multi-variable risk assessment to optimize the use of screening and early detection strategies in prostate cancer.
- Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
Institutes: 1University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, 2Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, United Kingdom, 3University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom, 4University of Bristol, School of Social and Community Medicine, Bristol, United Kingdom, 5University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom
Institutes: 1Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, 2Sahlgrenska Academy, Dept. of Urology, Gothenburg, Sweden, 3Sahlgrenska Academy, Dept. of Oncology, Gothenburg, Sweden, 4Memorial Sloan Kettering Cancer Center, Dept. of Surgery, Malmö, Sweden
Institutes: 1Rabin Medical Center, Dept. of Urology, Petah Tikva, Israel, 2Rabin Medical Center, Dept. of Imaging, Petah Tikva, Israel, 3Rabin Medical Center, The Raphael Recanati Genetics Institute, Petah Tikva, Israel
Institutes: 1Brigham and Women’s Hospital, Harvard Medical School, Division of Urological Surgery and Center For Surgery and Public Health, Boston, United States of America, 2Brigham and Women’s Hospital, Center for Surgery and Public Health, Boston, United States of America, 3Uniformed Services University of The Health Sciences, Dept. of Surgery, Bethesda, United States of America, 4Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Dept. of Medical Oncology, Boston, United States of America, 5Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, 6University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 7Henry Ford Health System, VUI Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, 8Uniformed Services University of The Health Sciences, Dept. of Preventive Medicine and Biostatistics, Bethesda, United States of America
Institutes: 1Brest University Hospital, Dept. of Urology, Brest, France, 2Brest University Hospital, Nuclear Medecine Laboratory, Brest, France, 3Tenon University Hospital, CeRePP (Centre De Recherche Sur Les Pathologies Prostatiques), Paris, France, 4Dijon University Hospital, Dept. of Urology, Dijon, France, 5Tenon University Hospital, Dept. of Urology, Paris, France
Institutes: 1Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, 2Memorial Sloan Kettering Cancer Center, Dept. of Biostatistics, New York, United States of America, 3Lund University, Clinical Microbiology, Malmo, Sweden
Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Vita-Salute University San Raffaele, Dept. of Radiology, Milan, Italy
Institutes: 1Tampere University Hospital, Dept. of Urology, Tampere, Finland, 2University of Tampere, School of Medicine, Tampere, Finland, 3Finnish Cancer Registry, Dept. of Research, Helsinki, Finland, 4Helsinki University, School of Medicine, Helsinki, Finland, 5Helsinki University Hospital, Dept. of Biochemistry, Helsinki, Finland, 6University of Tampere, School of Health Sciences, Tampere, Finland
Institutes: 1Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland, 2Cantonal Hospital Aarau, Dept. of Laboratory Medicine, Aarau, Switzerland, 3Cantonal Hospital Aarau, Dept. of Pathology, Aarau, Switzerland, 4Academic Hospital Braunschweig, Dept. of Urology, Braunschweig, Germany
Institutes: 1Tata Memorial Hospital, Dept. of Surgical Oncology(urooncology), Mumbai, India, 2Tata Memorial Hospital, Dept. of Surgical Oncology, Mumbai, India, 3Tata Memorial Hospital, Dept. of Radiation Oncology, Mumbai, India, 4AJ Shetty Hospital, Dept. of Surgical Oncology, Mangalore, India, 5Tata Memorial Hospital, Dept. of Surgical Pathology, Mumbai, India
Institutes: 1University of California, Dept. of Urology, San Francisco, United States of America, 2GenomeDx, San Diego, United States of America, 3UCSF, Dept. of Urology, San Francisco, United States of America, 4GenomeDx, , San Diego, United States of America
Institutes: 1University of Düsseldorf, Dept. of Urology, Düsseldorf, Germany, 2German Cancer Research Center Heidelberg, Division of Cancer Epidemiology (C020), Heidelberg, Germany, 3Technische Universitaet Muenchen, Dept. of Urology, Munich, Germany, 4Hanover Medical School, Dept. of Urology, Hanover, Germany, 5University of Heidelberg, Dept. of Urology, Heidelberg, Germany, 6University of Bonn, Dept. of Urology, Bonn, Germany, 7University of Bonn, Dept. of Pathology, Bonn, Germany, 8University of Düsseldorf, Dept. of Diagnostic and Interventional Radiology, Düsseldorf, Germany